U.S. Wireless Telecom Stock News

NasdaqCM:HYMC
NasdaqCM:HYMCMetals and Mining

Do Hycroft Mining (HYMC) Brimstone Drill Gains Recast the Scale of Its Silver-Gold Narrative?

Hycroft Mining Holding Corporation recently reported additional high-grade silver drill results from its 2025–2026 program at the Brimstone area of the Hycroft Mine in Nevada, confirming the silver system extends about 150 meters deeper, remains open laterally, and supports the company’s structural model for the high-grade zone. These results, alongside a very large 55% increase in measured and indicated gold and silver resources to 16.4 million ounces of gold and 562.6 million ounces of...
NYSE:NEM
NYSE:NEMMetals and Mining

Newmont (NEM) Valuation Check After Gold Price Slump And Interest Rate Jitters

Gold producer Newmont (NEM) is back in focus after its shares dropped sharply alongside a steep fall in bullion prices, as rising Middle East tensions and expectations for prolonged higher US interest rates pressured the sector. See our latest analysis for Newmont. The latest drop comes on top of a 13.35% 7 day share price decline and an 18.89% 30 day share price decline, yet Newmont still has a 110.41% 1 year total shareholder return. This suggests that short term momentum has cooled after a...
NYSE:AVTR
NYSE:AVTRLife Sciences

Is It Time To Reconsider Avantor (AVTR) After A 53% One Year Share Price Decline

If you are wondering whether Avantor's current share price reflects its true worth, the recent valuation checks offer some clear signals to unpack. The stock last closed at US$7.61, with returns of 3.7% decline over 7 days, 15.9% decline over 30 days, 33.6% decline year to date, and 53.3% decline over the past year, which can change how investors think about both risk and potential reward. Recent coverage has focused on Avantor's position in life sciences tools and services and how the...
NYSE:CAG
NYSE:CAGFood

Evaluating Conagra Brands (CAG) After Prolonged Share Price Weakness And Discounted Valuation

Event context and recent stock performance Conagra Brands (CAG) has been under pressure recently, with the share price closing at US$15.40 and showing negative returns over the past week, month and past 3 months. Those shorter term moves sit alongside a negative 1 year total return of about 36% and a negative 3 year total return of about 50%, prompting investors to reassess how the packaged food group’s fundamentals and valuation line up. See our latest analysis for Conagra Brands. Recent...
NasdaqGS:TSHA
NasdaqGS:TSHABiotechs

Taysha Gene Therapies Q4 Loss Of US$27.9m Tests Bullish TSHA 102 Narrative

Taysha Gene Therapies (TSHA) has wrapped up FY 2025 with Q4 revenue of US$5.5 million and a basic EPS loss of US$0.08, alongside a full year trailing revenue base of US$9.8 million and a trailing EPS loss of US$0.34 that keeps profitability firmly out of reach for now. Over recent quarters, the company has seen revenue move between US$0 and US$5.5 million while quarterly basic EPS losses ranged from about US$0.08 to US$0.10. This sets a clear picture of a business still in heavy investment...
NasdaqCM:SMPL
NasdaqCM:SMPLFood

A Look At Simply Good Foods (SMPL) Valuation After Jefferies Upgrade On Protein Growth Story

Jefferies’ recent upgrade of Simply Good Foods (SMPL), highlighting its focus on protein-centric products and the role of the Quest brand in key categories, has put fresh attention on the stock. See our latest analysis for Simply Good Foods. The Jefferies upgrade and upcoming Q2 FY2026 results come after a period where the 1-year total shareholder return of Simply Good Foods is down 56.24%, and the 90-day share price return of negative 25.76% contrasts with a recent 1-day gain of 1.60%,...
NYSE:GEV
NYSE:GEVElectrical

A Look At GE Vernova (GEV) Valuation After Its Upgraded Long Term Growth Outlook

GE Vernova (GEV) has become a focal point after management refreshed its growth outlook through 2028, linking higher margin and cash flow expectations to a growing backlog, robust orders, and exposure to data centers and nuclear power. See our latest analysis for GE Vernova. That refreshed outlook adds to very strong recent performance, with the share price delivering a 90 day share price return of 33.29% and a 1 year total shareholder return of 161.26%, which indicates rising growth...
NYSE:RYN
NYSE:RYNSpecialized REITs

Assessing Rayonier (RYN) Valuation After Recent Share Price Weakness

Rayonier (RYN) has been drawing attention after a period of weaker share performance, with the stock showing negative returns over the past month, past 3 months and year, even as revenue and net income figures remain available. See our latest analysis for Rayonier. At a share price of US$19.90, Rayonier has seen a 15.86% 1 month share price decline and a 7.91% year to date share price decline. The 1 year total shareholder return is down 21.63%, which points to fading momentum as the market...
NYSE:CRGY
NYSE:CRGYOil and Gas

Assessing Crescent Energy (CRGY) Valuation As Earnings Outlook Improves And Debt Profile Is Reshaped

Crescent Energy (CRGY) has come into focus after increasing the size of a $600 million convertible senior notes offering at a 2.75% interest rate, as management emphasizes debt maturity extension and balance sheet strengthening. See our latest analysis for Crescent Energy. The recent upsized convertible notes issue and focus on deleveraging come against a backdrop of strong momentum. Crescent Energy’s 30 day share price return is 22.99% and its 90 day share price return is 52.17%, while the 1...
NasdaqGM:RDNT
NasdaqGM:RDNTHealthcare

How RadNet’s AI Push and Gleamer Deal At RadNet (RDNT) Has Changed Its Investment Story

Earlier in March, RadNet, Inc. participated in Barclays’ Global Healthcare Conference and KeyBanc’s Healthcare Virtual Forum, where Executive Vice President and CFO Mark Stolper outlined the company’s plans across its outpatient imaging and digital health businesses. During these appearances, RadNet emphasized its push into radiology AI, highlighting the Gleamer acquisition as a key step in expanding its DeepHealth platform globally. We’ll now examine how RadNet’s AI-focused expansion,...
NYSE:STZ
NYSE:STZBeverage

Constellation Brands Puts Pacifico At Center Of 2027 Growth Trade Off

Constellation Brands, NYSE:STZ, has outlined new growth projects and marketing plans centered on its Pacifico beer brand as part of its 2027 strategy. The company is preparing targeted campaigns and new pack sizes around upcoming global events such as the World Cup, with an eye on volume recovery for Pacifico. Management has also indicated an adjustment to long term margin targets in response to shifting cost pressures and competition. For investors watching NYSE:STZ, the update comes with...
NYSE:EOG
NYSE:EOGOil and Gas

A Look At EOG Resources (EOG) Valuation As Rising Oil And Analyst Upgrades Lift The Stock

Escalating conflict in Iran has pushed Brent crude above US$100 per barrel. EOG Resources (EOG) is in focus as investors weigh how higher prices and improving analyst sentiment may influence its cash generation. See our latest analysis for EOG Resources. Those stronger oil prices and a string of supportive analyst updates have coincided with a sharp move in EOG, with a 15.9% 1 month share price return and a 36.2% 3 month share price return. The 5 year total shareholder return of 142.7% points...
NasdaqCM:AHG
NasdaqCM:AHGHealthcare

Akso Health Group (AHG) Valuation Check As Shares Hit A New 52 Week High On Strong Revenue Growth

Akso Health Group (AHG) recently hit a new 52 week high at US$2.10, alongside reported 75.6% revenue growth and a 30% total return over the past year, despite a thin 1% gross margin. See our latest analysis for Akso Health Group. The latest move to US$2.42 comes after a strong run, with an 84.7% 1 month share price return and a 51.3% year to date share price return. The 1 year total shareholder return of 92.1% and very large 3 year total shareholder return suggest momentum has been building...
NYSE:RHLD
NYSE:RHLDProfessional Services

Assessing Resolute Holdings Management (RHLD) Valuation After Recent Share Price Pullback

Resolute Holdings Management (RHLD) has drawn fresh attention after recent trading left the stock with a 9% decline over the past month and a 24% decline over the past three months, sharpening focus on its valuation profile. See our latest analysis for Resolute Holdings Management. Despite the recent 30 day and 90 day share price returns of 8.6% and 24.6% declines, respectively, the 1 year total shareholder return of about 3.7x and the latest $164.17 share price point to fading short term...
NYSE:ARX
NYSE:ARXInsurance

Accelerant Holdings (ARX) Revenue Surges To US$326.9 Million Challenging Bearish Loss Narratives

Accelerant Holdings (ARX) closed FY 2025 with fourth quarter revenue of US$326.9 million and a basic EPS loss of US$0.0027, while the trailing twelve month figures showed revenue of US$912.9 million and a basic EPS loss of US$7.49. Over recent periods, the company has seen quarterly revenue move from US$181.2 million in Q4 2024 to US$163.5 million in Q1 2025, US$204.7 million in Q2 2025, US$217.8 million in Q3 2025 and US$326.9 million in Q4 2025, with EPS shifting from US$10.57 in Q4 2024 to...
NasdaqGS:LCID
NasdaqGS:LCIDAuto

Lucid Group (LCID) Valuation Check As Weak Long Term Momentum Meets Revenue Growth And Heavy Losses

Lucid Group (LCID) continues to draw attention from EV investors, with shares most recently closing at US$10.30. Recent returns include a single-day gain of 3.5% and a decline of 12.9% over the past three months. See our latest analysis for Lucid Group. The recent 3.5% one day share price return and 4.7% 7 day share price return contrast with a 12.9% 90 day share price decline and a 54.8% 1 year total shareholder return loss. This suggests momentum has been weak over the longer term. If...
NasdaqGM:PTGX
NasdaqGM:PTGXBiotechs

A Look At Protagonist Therapeutics (PTGX) Valuation After ICOTYDE Receives U.S. FDA Approval

FDA approval sets new context for Protagonist Therapeutics The recent U.S. FDA approval of ICOTYDE for moderate to severe plaque psoriasis is a major regulatory milestone for Protagonist Therapeutics (PTGX). This development is putting fresh attention on the company’s commercial potential and broader pipeline. See our latest analysis for Protagonist Therapeutics. The FDA approval has arrived after a strong run in the shares, with a 23.31% 1 month share price return and a 91.67% 1 year total...
NasdaqCM:LE
NasdaqCM:LESpecialty Retail

Lands' End (LE) Q4 EPS Rebound Tests Bullish Margin Expansion Narrative

Lands' End (LE) has rounded out FY 2026 with Q4 revenue of US$462.4 million and basic EPS of US$0.40, supported by net income of US$12.3 million. Over recent quarters, the company has seen revenue move from US$261.2 million in Q1 2026 to US$317.5 million in Q3 2026 before reaching US$462.4 million in Q4. Quarterly EPS shifted from a loss of US$0.27 in Q1 to a profit of US$0.40 in Q4. For investors, the focus now is on how sustainable these earnings are given the thin trailing net profit...
NasdaqGS:JKHY
NasdaqGS:JKHYDiversified Financial

Is Jack Henry And Associates (JKHY) Fairly Priced After Recent Share Price Weakness?

Wondering if Jack Henry & Associates is priced attractively or already fully valued at around US$164 a share? This article breaks down what that current price might imply about the stock. The share price has moved by a 1.1% decline over the last week, a 3.7% gain over the last 30 days, and a 7.8% decline year to date, with a 4.9% decline over the last year and returns of 16.7% over three years and 14.6% over five years. That mix of shorter term weakness and longer term gains provides context...
NasdaqGS:STLD
NasdaqGS:STLDMetals and Mining

Is It Time To Reassess Steel Dynamics (STLD) After Recent Tariff Headlines And Price Pullback

If you are wondering whether Steel Dynamics at around US$167.56 is offering fair value or not, the key is to separate short term noise from the longer term valuation picture. The share price has seen a 4.3% decline over the last 7 days and a 12.7% decline over the last 30 days, even though the 1 year return sits at 34.2% and the 5 year return is 281.7%. Recent news coverage has focused on Steel Dynamics as a major US steel producer, with attention on how its capital allocation, capacity...
NYSE:VRT
NYSE:VRTElectrical

Is It Too Late To Look At Vertiv Holdings Co (VRT) After Its 200% One Year Surge?

Curious whether Vertiv Holdings Co at around US$269 per share is still offering value after such a strong run, or if you are late to the story. The stock has recently posted returns of 1.4% over 7 days, 10.5% over 30 days, 53.3% year to date and 202.5% over the last year, with a very large 3 year gain and strong 5 year performance. Recent coverage has focused on Vertiv as a key player supplying critical power and cooling infrastructure for data centers and AI related workloads, which has...
NYSE:NU
NYSE:NUBanks

Is It Too Late To Consider Nu Holdings (NU) After Recent Share Price Pullback?

If you are wondering whether Nu Holdings at US$14.16 still offers value or if most of the easy gains are already behind it, this article walks through what the current price might be implying. The stock is up 1.4% over the past week, while showing a 15.8% decline over the last month and a 16.8% decline year to date, set against a 24.2% return over the past year and a very large three-year gain of around 3x. Recent coverage of Nu Holdings has focused on its position as a fast-growing digital...
NYSE:COTY
NYSE:COTYPersonal Products

A Look At Coty (COTY) Valuation After Recent Share Price Weakness

Assessing Coty after recent share price pressure Coty (COTY) has come under pressure recently, with the share price showing negative returns over the past month, past 3 months and year. For investors, the key question is whether current levels fairly reflect its fundamentals. See our latest analysis for Coty. At a share price of US$2.15, Coty’s recent 30 day share price return of a 16.02% decline and year to date share price return of a 30.87% decline point to fading momentum and a weaker 1...
NasdaqCM:EOSE
NasdaqCM:EOSEElectrical

A Look At Eos Energy Enterprises (EOSE) Valuation After Class Action Lawsuit And Guidance Shortfall

What Triggered The Latest Focus On Eos Energy Enterprises (EOSE)? A new class action lawsuit against Eos Energy Enterprises (EOSE) has sharpened attention on the stock after allegations that earlier statements about production capabilities and financial guidance did not match later disclosures. The suit follows the company’s fourth quarter and full year 2025 update, where reported revenue of US$114.2 million was below prior guidance and management outlined production inefficiencies and...